Psilocybin is under clinical development by Tryp Therapeutics and currently in Phase II for Binge Eating Disorder. According to GlobalData, Phase II drugs for Binge Eating Disorder have a 69% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Psilocybin’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Psilocybin overview

Psilocybin (TRP-8802) is under development for the treatment of fibromyalgia, binge eating disorder, hypothalamic obesity and chronic pain conditions. It is administered orally as a capsule and also administered intravenously. It is a psychedelic drug.

Tryp Therapeutics overview

Tryp Therapeutics (TYRP) is a pharmaceutical company which deals with clinical-stage biotech company. The company is headquartered in Kelowna, British Columbia, Canada.

For a complete picture of Psilocybin’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.